• Help people with EB

    Your support of DEBRA International or a national EB group enables us to provide the best quality of life for families and individuals affected by EB.

Donation Account: IBAN AT65 6000 0005 1004 5254, BIC BAWAATWW, DEBRA International, Am Heumarkt 27/1, 1030 Vienna

donate now


Cell-based therapies for epidermolysis bullosa – from bench to bedside

This overview highlights cell-based approaches that have recently been tested in pilot clinical trials, attesting to the potential of regenerative medicine for blistering skin diseases.

Significant progress has been made over the past two decades in molecular genetics of epidermolysis bullosa (EB), a group of heritable blistering disorders, with diagnostic and prognostic implications. More recently, novel molecular approaches have been developed towards potential treatment of EB, with emphasis on gene-, protein-, and cell-based strategies.

Regenerative medicine for heritable skin diseases is moving very rapidly, and as illustrated by EB, several approaches have recently entered the clinical arena. It is conceivable that with the advent of these technological innovations, we are making significant progress towards treating and potentially curing these currently intractable disorders.

Read full article:
Uitto J, Has C, Bruckner-Tuderman L (2012): Cell-based therapies for epidermolysis bullosa – from bench to bedside. JDDG 2012: Vol 10/11: 803-807

Icon "blue butterfly"